細(xì)胞名稱： 人結(jié)腸腺癌細(xì)胞（STR鑒定正確）

細(xì)胞簡稱： SW480

細(xì)胞別稱： SW-480; SW 480; SW480E；sw480細(xì)胞

貨號：TCH-C348

規(guī)格： 1×10?cells/T25培養(yǎng)瓶

價格：1400元 (干冰運輸需另加200元干冰費)

種屬來源：人

組織來源：結(jié)腸

特征：結(jié)腸腺癌

細(xì)胞形態(tài)：上皮細(xì)胞樣

生長特性：貼壁生長

培養(yǎng)體系：L-15+10%FBS+1%P/S

配套培養(yǎng)基貨號：TCH-G348

傳代比例：1:3-1:6，每2-3天換液一次

傳代周期：48-72 h

培養(yǎng)條件：氣相：空氣，溫度：37℃

凍存條件：60%基礎(chǔ)培養(yǎng)基+30%FBS+10%DMSO，液氮儲存

質(zhì)量檢測：細(xì)菌、真菌、支原體檢測均為陰性

   sw480細(xì)胞源自一位51歲白人男性的原位直腸腺癌，而SW620源自同一病人一年后的淋巴結(jié)轉(zhuǎn)移灶。該細(xì)胞CSAp和直腸抗原3陰性；角蛋白陽性；p53基因第273位密碼子的G→A突變引起Arg→His替代，309位密碼子的C→T突變導(dǎo)致Pro→Ser替代；細(xì)胞p53蛋白表達(dá)水平升高；癌基因c-myc、K-ras、H-ras、N-ras、myb、sis和fos的表達(dá)呈陽性；未檢測到癌基因N-myc的表達(dá)；不表達(dá)Matrilysin（一種與腫瘤侵襲相關(guān)的金屬蛋白酶）。有報道稱該細(xì)胞表達(dá)GM-CSF。

  sw480細(xì)胞 L-15空氣培養(yǎng)注意要點：

1. 空氣培養(yǎng)注意要點： 

a) 人結(jié)腸腺癌細(xì)胞（SW480）使用L15空氣培養(yǎng)基。 L-15 采用磷酸鹽和游離氨基酸而非進(jìn)行緩沖。這種培養(yǎng)基適用 于支持非 CO2 平衡環(huán)境中的細(xì)胞生長。在使用該培養(yǎng)體系時，須將培養(yǎng) 箱的二氧化碳濃度調(diào)節(jié)至“0"（維持空氣培養(yǎng)狀態(tài)），如果通入5%二氧化 碳通過培養(yǎng)基對細(xì)胞產(chǎn)生毒性。

 b) 如您沒有無空氣培養(yǎng)箱，可選擇使用不透氣培養(yǎng)瓶（密封瓶蓋）培養(yǎng)該 細(xì)胞，并將瓶蓋擰緊，每次操作時開蓋短時間接觸到的二氧化碳不影響該細(xì)胞正常培養(yǎng)。

         圖示：密封瓶蓋培養(yǎng)瓶（左）和透氣瓶蓋培養(yǎng)瓶（右）

 注意：可以選用 SW480細(xì)胞專用培養(yǎng)基（即用型培養(yǎng)基）： 已添加血清和雙抗等成分，可直接用于培養(yǎng)SW480細(xì)胞。

參考文獻(xiàn)：

"Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871

Goodfellow M, et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed:

Lelbovitz A, et al. Detection and analysis of a glucose 6-phosphate dehydrogenase phenotype B cell line contamination. J. Natl. Cancer Inst. 63: 635-645, 1979. PubMed: 288927

Adachi A, et al. Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J. Virol. 61: 209-213, 1987. PubMed: 3640832

Schroy PC, et al. Detection of p21ras mutations in colorectal adenomas and carcinomas by enzyme-linked immunosorbent assay. Cancer 76: 201-209, 1995. PubMed: 8625092

Trainer DL, et al. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int. J. Cancer 41: 287-296, 1988. PubMed: 3338874

Weiss J, et al. Mutation and expression of the p53 gene in malignant melanoma cell lines. Int. J. Cancer 54: 693-699, 1993. PubMed: 8514460

Nigro JM, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-707, 1989. PubMed: 2531845

Barnett SW, et al. Characterization of human immunodeficiency virus type 1 strains recovered from the bowel of infected individuals. Virology 182: 802-809, 1991. PubMed: 2024498

Leibovitz A, et al. Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 36: 4562-4569, 1976. PubMed: 1000501

Geiser AG, et al. Suppression of tumorigenicity in human cell hybrids derived from cell lines expressing different activated ras oncogenes. Cancer Res. 49: 1572-1577, 1989. PubMed: 2647289

Lahm H, et al. Secretion of bioactive granulocyte-macrophage colony-stimulating factor by human colorectal carcinoma cells. Cancer Res. 54: 3700-3702, 1994. PubMed: 8033086

Rodrigues NR, et al. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA 87: 7555-7559, 1990. PubMed: 1699228

Santoro IM, Groden J. Alternative splicing of the APC gene and its association with terminal differentiation. Cancer Res. 57: 488-494, 1997. PubMed: 9012479

Tsao H, et al. Novel mutations in the p16/CDKN2A binding region of the Cyclin-dependent Kinase-4 gene. Cancer Res. 58: 109-113, 1998. PubMed: 9426066

Zhu X, et al. Cell cycle-dependent modulation of telomerase activity in tumor cells. Proc. Natl. Acad. Sci. USA 93: 6091-6095, 1996. PubMed: 8650224

Witty JP, et al. Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res. 54: 4805-4812, 1994. PubMed: 8062282"